BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18055341)

  • 1. Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy.
    Navarro JT; Ribera JM; Oriol A; Xicoy B; Mate JL; Sirera G; Lloveras N; Millá F; Feliu E
    Int J Hematol; 2007 Nov; 86(4):337-42. PubMed ID: 18055341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone.
    Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Flores A; Millá F; Feliu E
    Br J Haematol; 2001 Mar; 112(4):909-15. PubMed ID: 11298585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival--results of the German Multicenter Trial.
    Weiss R; Mitrou P; Arasteh K; Schuermann D; Hentrich M; Duehrsen U; Sudeck H; Schmidt-Wolf IG; Anagnostopoulos I; Huhn D
    Cancer; 2006 Apr; 106(7):1560-8. PubMed ID: 16502436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
    Vaccher E; Spina M; di Gennaro G; Talamini R; Nasti G; Schioppa O; Vultaggio G; Tirelli U
    Cancer; 2001 Jan; 91(1):155-63. PubMed ID: 11148572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
    Ratner L; Lee J; Tang S; Redden D; Hamzeh F; Herndier B; Scadden D; Kaplan L; Ambinder R; Levine A; Harrington W; Grochow L; Flexner C; Tan B; Straus D;
    J Clin Oncol; 2001 Apr; 19(8):2171-8. PubMed ID: 11304769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505.
    Itoh K; Ohtsu T; Fukuda H; Sasaki Y; Ogura M; Morishima Y; Chou T; Aikawa K; Uike N; Mizorogi F; Ohno T; Ikeda S; Sai T; Taniwaki M; Kawano F; Niimi M; Hotta T; Shimoyama M; Tobinai K;
    Ann Oncol; 2002 Sep; 13(9):1347-55. PubMed ID: 12196359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
    Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
    Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
    Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
    Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicpathological features and survival of patients with AIDS related non-Hodgkin's lymphoma].
    Sun KY; Gui XE; Deng D; Xiong Y; Deng LP; Gao SC; Zhang YX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):97-101. PubMed ID: 28279031
    [No Abstract]   [Full Text] [Related]  

  • 10. The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.
    Portlock CS; Qin J; Schaindlin P; Roistacher N; Myers J; Filippa D; Louie D; Zelenetz AD; O'Brien JP; Moskowitz C; Norton L; Yahalom J; Straus DJ; Bertino JR
    Ann Oncol; 2004 Oct; 15(10):1495-503. PubMed ID: 15367410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
    Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
    Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma.
    Toffoli G; Corona G; Cattarossi G; Boiocchi M; Di Gennaro G; Tirelli U; Vaccher E
    Ann Oncol; 2004 Dec; 15(12):1805-9. PubMed ID: 15550586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
    Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Hodgkin's lymphoma among patients infected with human immunodeficiency virus: the experience of a single center in Brazil.
    Tanaka PY; Pracchia LF; Calore EE
    Int J Hematol; 2006 Nov; 84(4):337-42. PubMed ID: 17118760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
    Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
    Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III of Study of R-CHOP-21 vs R-CHOP-14 for Untreated Stage III and IV B-cell Non-Hodgkin's Lymphoma: a Report from Iran.
    Payandeh M; Najafi S; Shojaiyan FZ; Sadeghi M
    Asian Pac J Cancer Prev; 2016; 17(3):1513-7. PubMed ID: 27039799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.